0838 GMT - Bayer's prospects are improving, Berenberg analyst Sebastian Bray says in a note, citing a promising late-stage stroke prevention trial. Although the German pharmaceutical and agricultural conglomerate's late-stage trial for secondary stroke prevention is considered a long shot, there is a possibility of unexpected upside by the year end if the treatment proves significantly better than the placebo, the analyst says. "We believe there is an outside chance of a positive outcome for Bayer that may move the market's view of annual peak sales for the drug from very little to 1 billion euros or more," he says. In addition, if a Russia-Ukraine peace agreement doesn't cause a major drop in soft commodity prices, Bayer's earnings are unlikely to significantly decrease further, the analyst adds. Shares are up 1.7% at 23.65 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 10, 2025 04:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.